secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2023-09-05T23:59:59+00:00
Accession:  0001213900-23-073586
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics presents updated INT230-6 data: Phase 3 sarcoma trial planned; tumor necrosis in breast cancer
--------------------------------------------------------------------------------

- INT230-6 induced up to 95% tumor necrosis in presurgical breast cancer after 1-2 injections; safety profile favorable.
- Phase 3 soft tissue sarcoma trial designed; median OS not reached vs synthetic control median of 205 days.
- Phase 1/2 IT-01 study in 110 patients with 25 tumor types completed; database locked; data presented at ASCO and SITC.
- Phase 2/3 breast cancer study designed; data expected Q4 2023; accelerated approval path via pCR discussed with FDA.
- Company to present at H.C. Wainwright conference on Sept 11, 2023; one-on-one meetings available.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000121390023073586/0001213900-23-073586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000121390023073586/ea184623-8k_intensity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-073586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer